The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8‐week, prospective, open‐label, multicenter, single‐arm study
INTRODUCTION
This study evaluated the effectiveness and safety of amisulpride in Chinese schizophrenia patients.


METHODS
A multicenter, single-arm Phase IV study (NCT01795183). Chinese patients with schizophrenia received amisulpride for 8 weeks. The primary endpoint was ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8.


RESULTS
A total of 316 patients were enrolled; 295 were included in the effectiveness analysis; 66.8% (197/295) achieved ≥50% decrease in Positive and Negative Syndrome Scale total score from Baseline to Week 8. Nine patients discontinued treatment because of adverse events.


DISCUSSION
Amisulpride had clinical effectiveness and was relatively well tolerated in Chinese patients with schizophrenia.